Ofatumumab for refractory opsoclonus‐myoclonus syndrome following treatment of neuroblastoma. Issue 12 (29th June 2013)

• Record Type: Journal Article
• Authors: Ketterl, Tyler G.; Messinger, Yoav H.; Niess, Dawn R.; Gilles, Elizabeth; Engel, William Keith; Perkins, Joanna L.
• Is Part Of: Pediatric blood & cancer. Volume 60:Issue 12(2013:Dec.)
• Page Start: E163
• Page End: E165
• Publication Date: 2013-06-29
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.24646
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc24646-sec-0001" sec-type="section"> <p>Opsoclonus‐myoclonus syndrome (OMS) may be associated with ANNA‐1 (anti‐Hu) autoantibodies. The standard treatment with IVIG, steroids, and anti‐CD20 monoclonal antibody may fail, and optimal therapy is unknown. A patient developed OMS with high‐titer ANNA‐1 following recovery from neuroblastoma. She failed standard therapy and had only transient response to rituximab. Treatment with the humanized anti‐CD20 monoclonal antibody ofatumumab combined with methotrexate resulted in transient neurologic improvement and decrease of ANNA‐1. This suggests that ofatumumab combined with methotrexate should further be considered OMS patients, particularly in refractory disease. Pediatr Blood Cancer 2013;60:E163–E165. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>